---
title: "Consensus Guideline for Safe Implementation of Personalized Bacteriophage Therapy"
id: "nature-0-a-consensus-based-guideline-for-personalized-bacteriophage-therapy"
canonical_url: "https://medichelpline.com/clinical-feed/nature-0-a-consensus-based-guideline-for-personalized-bacteriophage-therapy"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04654-6"
published_at: "2026-09-21T11:53:47.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Consensus Guideline for Safe Implementation of Personalized Bacteriophage Therapy
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-0-a-consensus-based-guideline-for-personalized-bacteriophage-therapy
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04654-6)
- **Published At:** 2026-09-21T11:53:47.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The guideline provides a structured, consensus-based framework for **personalized phage therapy** to address barriers to clinical implementation amid rising **antimicrobial resistance**. - Developed under the AWMF methodology and led by the German Society for Infectious Diseases, the panel included 20 German medical societies, patient representatives, regulatory authorities and 18 international experts. - Over 60 recommendations cover core principles, infrastructure, phage preparation and quality control, clinical administration, monitoring and documentation, and research priorities. - Recommendations were formulated with graded wording (strong, conditional, optional) and consensus strength categories; statements without direct action were labeled as expository. - The guideline emphasizes individualized bacterial culture and timely **phage susceptibility** testing, interdisciplinary decision-making, and case-by-case use primarily when standard treatments have failed. - The document discusses regulatory challenges for personalized phage products, limitations of GMP-based pathways for individualized therapy, and the pragmatic role of **magistral preparation** and non-GMP approaches when quality standards are maintained. - Infrastructure recommendations call for access to phage screening laboratories, quality-controlled preparation facilities, and an interdisciplinary phage therapy board; external laboratory support is acceptable if timely. - Standardized methods, interlaboratory proficiency testing and comprehensive case registries are stressed to improve reproducibility, traceability and data collection for future evaluation. - Evidence summarized indicates a generally favorable safety profile for phage therapy, but heterogeneous efficacy data and trial-design limitations underscore the need for optimized strategies and well-designed prospective studies. - Guideline validity runs from 5 January 2026 to 29 June 2030, with annual review of update needs; conflict-of-interest declarations were collected and assessed during development.
## Clinical Analysis & Structured Key Points
A consensus-based guideline for personalized bacteriophage therapy | Nature Medicine Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement A consensus-based guideline for personalized bacteriophage therapy Download PDF Download PDF Abstract Bacteriophages (phages) — viruses that selectively infect bacteria — are a promising option for personalized therapy of difficult-to-treat bacterial infections. Clinical implementation in many countries worldwide, however, faces multiple hurdles, including a lack of consensus on general principles for phage therapy, infrastructural requirements, procedures for quality-assured phage selection and preparation, clinical administration, monitoring and documentation. Existing guidance provides limited practical direction across the entire translational pathway and lacks inspection-ready specifications to support both pharmacies and clinical sites. These gaps impede safe and transparent clinical use and effective regulatory oversight. Likewise, there are no established processes to identify research questions that will be key to advancing clinical phage research in the future. To address these needs, this consensus-based guideline was developed within the methodological framework of the Association of the Scientific Medical Societies in Germany under the leadership of the German Society for Infectious Diseases. It was created through a collaborative effort involving 20 professional societies, patient advocacy groups and regulatory authorities and 18 international experts. The guideline provides over 60 recommendations on core principles, infrastructure, preparation and quality control, administration and future research. Recommendations are supported by international societies, organizations and stakeholders. By providing clear and practice-oriented recommendations, this consensus statement paves the way for the safe and standardized use of personalized phage therapy. Explore related subjects Discover the latest articles and news in related subjects. Health care Translational research Main The accelerating global crisis of antimicrobial resistance poses an existential threat to modern medicine, driving renewed interest in bacteriophage (phage) therapy as a targeted approach for the treatment of bacterial infections. Despite growing clinical use, often as a last-resort intervention, broader implementation of personalized phage therapy in many regions of the world remains constrained by the absence of clear, harmonized and practice-oriented guidance. This gap is becoming increasingly evident as physicians, pharmacists, patients and regulators seek structured pathways for integrating personalized phage therapy into clinical care when conventional antimicrobial options have failed. This guideline aims to address this unmet need by providing practical, consensus-based recommendations for safe and effective personalized phage therapy in Germany and beyond. It focuses on core principles underpinning phage therapy, infrastructural and organizational requirements, standards for phage preparation and quality control, clinical administration considerations and priorities for future translational and clinical research. This document seeks to translate foundational principles into actionable guidance applicable to real-world clinical settings. The guideline was developed by an international and interdisciplinary group of experts. This collaboration integrated clinical expertise in infectious diseases, clinical microbiology and various medical specialties with technical knowledge in pharmacology, toxicology and biotechnology as well as regulatory and quality affairs. National and international phage experts, as well as representatives from patient advocacy groups, were actively involved from an early stage to ensure inclusivity, relevance and alignment with clinical and societal needs. The final recommendations have been reviewed and supported by additional key international societies, organizations and stakeholders, underscoring their broad acceptance and applicability. All recommendations were formulated using a structured, consensus-based methodology in accordance with the standards of the Association of the Scientific Medical Societies in Germany (AWMF) for consensus-based guidelines. Structured consensus techniques were applied under neutral moderation by AWMF representatives to ensure transparency, rigor and balance. Given the biological, clinical and regulatory complexity of phage therapy, as well as the limited available evidence, this guideline does not aim to be exhaustive or to address every possible clinical scenario. Rather, it provides a structured framework to support clinicians, pharmacists, researchers and policymakers in navigating the key challenges of personalized phage therapy and advancing its responsible integration into contemporary medical practice. Methodology This consensus guideline was developed within the structured methodological framework of the AWMF under the leadership of the German Society for Infectious Diseases (Deutsche Gesellschaft für Infektiologie e.V. (DGI)). The panel comprised representatives from 20 German medical societies, German patient representatives and experts from national and international institutions and authorities, including German regulatory agencies and academic centers (Supplementary Methods, Tables 1 and 2 ). A steering committee (Supplementary Methods, Table 3 ) supervised the process, supported by neutral methodological guidance from AWMF representatives. Six topic-specific working groups were convened (Supplementary Methods, Table 4 ). After an initial online meeting defining key questions and literature search strategies, each working group conducted independent literature reviews and drafted recommendations with supporting background texts. Recommendations were discussed and voted on during six online consensus conferences neutrally moderated by an AWMF representative. Voting included plenary discussion, amendments where necessary and formal voting. The strength of recommendations was determined by standardized wording and grading (Supplementary Methods, Table 5 ): strong recommendations were expressed using the wording ‘we recommend/we do not recommend’ or ‘should/should not’ (grade A); conditional recommendations were expressed using ‘we suggest’, ‘ought to’ or ‘can/cannot’ (grade B); and open recommendations were expressed using ‘may be considered’, ‘could be considered’ or ‘might be considered’ (graded as ‘Optional’). The strength of consensus was classified according to predefined categories (Supplementary Methods, Table 6 ) based on the proportion of approving participants: strong consensus (>95%), consensus (>75–95%), majority approval (>50–75%) and no consensus (≤50%). Expository content describing specific facts, circumstances or problems without direct recommendations for action was designated as ‘statements’; these did not require formal voting and were not assigned a formal level of evidence. The guideline is valid from 5 January 2026 to 29 June 2030. The revision will be initiated by the steering committee that will also review the need for updates to the guideline annually. Full methodological details are provided in the Supplementary Methods . All participants submitted conflict of interest (COI) declarations via the AWMF online portal (Supplementary File 1 ). Moderate COIs were identified for seven individuals, who were excluded from leadership roles. To assess any potential influence, the consensus analysis was repeated both including and excluding their votes. As the results were unchanged, their voting did not affect the final consensus outcomes. The guideline was externally reviewed, adopted by participating societies and circulated for review and support by international societies, organizations and stakeholders (Supplementary Methods, Tables 7 and 8 ). A list of important abbreviations commonly used throughout this paper is provided in the Supplementary Explanations . This guideline is directed at physicians involved in the treatment of bacterial infections in adult and pediatric patients, particularly those working in infectious disease management, antimicrobial stewardship and related medical and pharmaceutical fields. It further serves a broader audience, including clinicians outside the core specialties, pharmacists, patients and patient advocacy organizations, ethics committees, researchers in microbiology, infectious diseases and personalized medicine, regulatory bodies and public health authorities, policymakers, hospital administrators, health insurance providers and industry stakeholders in phage research and development. General considerations and regulatory frameworks for phage therapy Originally pioneered by Twort and d’Hérelle to combat enteric and wound infections, phage therapy fell out of favor during the antibiotic era. Today, however, the global crisis of antimicrobial resistance has sparked a renewed interest in these viral treatments 1 , 2 , 3 , 4 , 5 , 6 . Phages are abundant in nature and the human microbiome 7 , 8 , 9 , 10 , 11 , 12 , 13 , vary widely in structure and genome size and follow different life cycles, with lytic phages forming the basis of phage therapeutics 14 , 15 . Moreover, the potential for bacterial resistance to phages requires continued monitoring and iterative adjustment during treatment. Available evidence suggests that phage therapy is generally safe when produced and administered according to quality standards, and first considerations for the use of phage therapy in clinical practice have been suggested to inform clinicians 16 , 17 , 18 , 19 , 20 . In one series of 100 consecutive cases treated in Belgium, 77% of patients showed clinical improvement and 61% achieved bacterial eradication, with no serious phage-related adverse reactions 21 . Alongside the Belgian 100-patient case series, several systematic reviews have further characterized this field. A recent systematic review of safety and efficacy trials found that, although phage therapy is consistently reported to be safe in modern trials, efficacy has not been reliably demonstrated 22 . The authors attribute this discrepancy to key limitations in trial design, particularly the failure to deliver sufficient quantities of appropriately matched phages to the site of infection. Similarly, a systematic review focusing specifically on difficult-to-treat infections concluded that phage therapy shows a favorable safety profile and potential clinical benefit, particularly in compassionate-use settings, while emphasizing the heterogeneity of treatment approaches and the limited availability of controlled clinical data 20 . Collectively, these findings support the overall safety of phage therapy and its therapeutic promise while underscoring the need for optimized treatment strategies and well-designed prospective trials to better establish efficacy. Assessing phage activity relies on plaque, spot and liquid infection assays to generate phagograms, although reproducibility across laboratories remains limited. The standard authorization pathway for medicinal products, based on randomized controlled clinical trials using investigational medicinal products manufactured according to Good Manufacturing Practice (GMP), presents major challenges for personalized phage therapy 23 (Fig. 1 ). Phage specificity requires individualized matching, which, alongside dynamic bacteria–phage interactions and the need for treatment adaptation, limits the standardization and scalability of such trials. Although early-phase studies suggest a favorable safety profile, the highly individualized nature of these treatments remains fundamentally incompatible with current regulatory frameworks 24 , 25 , 26 , 27 , 28 , 29 , 30 . Fig. 1: Overview of two main strategies using phage therapy. Full size image This schematic compares two main strategies in phage therapy: personalized phage therapy, which involves selecting or isolating phages tailored to the bacterial pathogen causing an infection in an individual patient, and phage therapy in clinical trials. The latter typically involves broad host range phages that can benefit multiple patients, often utilizing a selection of several phages, sometimes even combined as a phage cocktail. ‘Emerging phage resistance’ occurs when bacterial populations evolve mechanisms to avoid being infected by phages during phage therapy, similar to the way bacteria develop resistance to antibiotics. Even outside the highly regulated environment of clinical trials, individualized phage administrations are often constrained by regulatory and practical barriers. GMP-grade phage manufacture is costly, time-consuming and often incompatible with the urgency and flexibility required for and during personalized therapy, making it feasible for only a small subset of patients when suitable GMP-grade phages are already available. Consequently, many personalized treatments have relied on non-GMP-grade phages, as documented in case reports worldwide 20 , 21 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 . Magistral preparation of phage active pharmaceutical ingredients (APIs) — the purified phage preparations used as starting materials — and phage therapy medicinal products (PTMPs), which are the finished formulations intended for patient administration, offers a pragmatic alternative, as such preparations are generally exempt from GMP requirements. For example, in the European Union, under Article 3(1) of Directive 2001/83/EC, personalized phage preparations compounded as magistral formulations on prescription fall under this exemption. Nevertheless, existing professional guidance provides insufficient detail to ensure the consistent preparation of phage APIs or PTMPs. Although the European Pharmacopoeia (Ph.Eur) has recently issued baseline guidance for phage therapy 16 , the lack of detailed, practice-oriented standards continues to limit broader implementation. In most countries worldwide, the cross-border transfer of magistral phage preparations to individual patients remains challenging. Inconsistencies in quality standards, restricted and inflexible manufacturing capacity, limitations in traceability and stability, including cold-chain requirements, liability and insurance issues related to transfers and logistical constraints at customs can all restrict flexibility and lead to substantial delays. Given the growing number of patient requests and the limitations of existing regulatory pathways, this guideline emphasizes immediately applicable, patient-individualized approaches that complement industrial phage development rather than awaiting future legislative changes that may not address urgent clinical needs. Recommendations on general principles of personalized bacteriophage therapy Phage therapy should be considered on a case-by-case basis, mainly for patients in whom standard-of-care treatments have failed or are contraindicated. Outside clinical trials, phage therapy is typically applied within the framework of individualized treatment attempts, particularly for difficult-to-treat infections, which can be caused, for example, by antibiotic-resistant or biofilm-forming bacteria 21 , 40 , 41 , 42 , 43 , 44 . Because phage therapy is highly specific (see also Supplementary Explanations, Fig. 1 ), successful treatment requires culture-based bacterial identification with species determination, followed by careful phage–bacteria matching. The susceptibility of the bacteria to the chosen phage(s) should be confirmed as close to treatment initiation as possible, as susceptibility to phages may change over time. In urgent situations, therapy may begin before susceptibility results are available and be adapted thereafter. In case of polymicrobial infections, all causative bacterial species should undergo phage susceptibility testing, as untreated bacteria may sustain an infection despite targeted therapy of a single organism, and comprehensive testing improves the likelihood of clinical success. Interdisciplinary discussions among treating physicians, microbiologists, infectious disease specialists and experts involved in phage selection, manufacturing, susceptibility testing and treatment are essential. When quality standards are met, phage therapy appears safe 16 , 17 , 18 , 20 . Despite limited evidence from clinical trials, the available data indicate no major safety concerns, including immunocompromised patients, children and pregnant or breastfeeding women 18 , 20 , 21 , 28 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 . Beyond biologically expected responses (for example, fever and increased byproducts due to bacterial breakdown), no clinically relevant drug interactions or allergic reactions attributable to phage therapy have been reported, although monitoring remains advisable 18 , 19 , 57 , 75 , 76 . The guideline team proposes the following recommendations and statements on general principles of personalized phage therapy (Table 1 ). The full set of background explanations is provided in Supplementary Explanations 1 . Table 1 Recommendations on general principles of personalized bacteriophage therapy Full size table Recommendations on infrastructure of personalized bacteriophage therapy Safe, efficient and scalable implementation of personalized phage therapy requires a coordinated infrastructure that integrates laboratory diagnostics, phage preparation and clinical expertise. Core elements include access to phage laboratories capable of performing phage screening and susceptibility testing, appropriate facilities for phage preparation with defined quality control and safety standards and an interdisciplinary phage therapy board that brings together relevant medical specialists, infectious diseases experts, microbiologists and pharmacists to guide clinical case assessment and individual treatment strategies (Supplementary Explanations, Fig. 2 ). These components form an ideal, flexible framework and do not need to be housed at a single site; certain elements, such as phage preparation, may be outsourced to specialized centers. Phage therapy is not limited to highly specialized centers, but any institution administering phages must meet minimum requirements, including appropriate storage conditions, medically qualified personnel and the ability to manage phage administration, safety monitoring, concomitant therapies and microbiological sampling. Institutions without in-house capacities for phage assays, such as susceptibility or phage–antibiotic synergy testing, may rely on external laboratories, provided results are available in a timely manner. Standardized and harmonized methods for phage susceptibility and potency testing are essential, with an emphasis on interlaboratory proficiency testing. Referential guidance may be provided through recommendations currently under development by the subcommittee on phage susceptibility testing of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 77 . Comprehensive documentation of phage therapy cases in national and/or international registries, including treatment protocols, outcomes and unexpected events, is considered essential to improve transparency, enable systematic evaluation and inform future practice 78 . High-quality and harmonized data collection is viewed as critical for the long-term success of personalized phage therapy. The recommendations and statements on infrastructure of personalized phage therapy are summarized in Tab
## Related Clinical Research

- [COVID-19 mortality among people with HIV in Florida before and after COVID-19 vaccine availability](https://medichelpline.com/clinical-feed/plos-one-13-covid-19-mortality-risk-among-people-with-hiv-in-florida-before-and-after-the.md)
- [Understanding Parasitic Identification in Delusional Parasitosis](https://medichelpline.com/clinical-feed/plos-one-21-bridging-perception-and-reality-parasitic-identification-in-delusional.md)
- [Distal IRF4 Regulatory Element Enables Inflammation-Driven Destabilization of Human Regulatory T C](https://medichelpline.com/clinical-feed/nature-immunology-0-deletion-of-a-distal-irf4-element-prevents-inflammation-induced-reprogramming.md)
- [Obesity-associated inflammation and cancer: mechanisms linking adipose immune changes to tumor risk](https://medichelpline.com/clinical-feed/frontiers-in-immunology-6-obesity-associated-inflammation-and-cancer-molecular-mechanisms-evidence-gaps.md)
- [Mycophenolate Mofetil for Steroid-Unresponsive ICI-Associated Transverse Myelitis: Case Report and](https://medichelpline.com/clinical-feed/frontiers-in-immunology-7-case-report-observational-use-of-mycophenolate-mofetil-in-probable-steroid.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.